NIAID/DMID/CASG Central Unit is a clinical research site located in Birmingham, Alabama, United States 35294.
Crixeo Health Trust Score: 59/100 (POOR). This profile has not yet been claimed by the site owner.
NIAID/DMID/CASG Central Unit has participated in 3 clinical trials.
Therapeutic areas: Hantavirus Pulmonary Syndrome, Papilloma, Cytomegalovirus Infections.
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID).
Trust Score: 59/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
NIAID/DMID/CASG Central Unit has a Crixeo Trust Score of 59/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
NIAID/DMID/CASG Central Unit has 3 clinical trials on record. Their work covers Hantavirus Pulmonary Syndrome, Papilloma, Cytomegalovirus Infections.
NIAID/DMID/CASG Central Unit has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.